Morgan Stanley raises target for Moderna stock from USD 89 to USD 95

Published on 10/08/2026 at 16:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 145.00 million. Moderna stock costs EUR 174.62 on October 8, 2026 after EUR 174.75, minus 0.07 percent.

Key points in brief

Morgan Stanley raised its Moderna target from USD 89.00 to USD 95.00 on October 7, 2026.
Second-quarter revenue reached USD 145.00 million, while the GAAP net loss was USD 782.00 million.
Moderna stock was at EUR 174.62 at Lang & Schwarz on October 8, 2026, minus 0.07 percent versus the prior close.
Nasdaq-100 inclusion is scheduled for October 9, 2026, ahead of detailed melanoma data on October 24, 2026.

Aquarellmalerei der Cambridge-Skyline mit modernen Forschungsgebäuden am Charles River — Moderna Inc. (US60770K1034) präsentiert eine stimmungsvolle Aquarell-Ansicht der Cambridge-Skyline mit modernen Biotech-Forschungsgebäuden am Flussufer, Illustration mit AI erstellt.

Moderna Inc. (US60770K1079) saw Morgan Stanley raise its price target from USD 89.00 to USD 95.00 on October 7, 2026, while keeping an Equal Weight rating, according to Markets Insider. The move gives Moderna stock a fresh analyst reference point as the company approaches major oncology and index events.

Three milestones shape the story

On July 31, 2026, Moderna reported second-quarter revenue of USD 145.00 million and a GAAP net loss of USD 782.00 million in its quarterly release carried by Access Newswire. On September 21, 2026, Moderna announced that three abstracts on intismeran autogene had been accepted for the European Society for Medical Oncology congress, including a Presidential Symposium, as reported by Newswire. On October 7, 2026, Morgan Stanley lifted the target from USD 89.00 to USD 95.00, according to Markets Insider.

What does the target change imply?

The revised USD 95.00 target remains below the USD 195.66 primary-market quote for Moderna on October 8, 2026 at 10:25 a.m. ET. The gap is 51.46 percent, calculated as the price below the target, which makes the upcoming clinical readout important for the valuation narrative.

Two dates carry the next catalysts

Nasdaq announced on October 1, 2026 that Moderna would join the Nasdaq-100 before the market open on October 9, 2026, replacing Warner Bros. Discovery, according to GlobeNewswire. The next dated company event is the October 24, 2026 ESMO presentation, when Moderna plans to show Phase 3 melanoma data and host an investor webcast, according to Newswire.

Moderna stock holds near EUR 175

At Lang & Schwarz, Moderna stock was trading at EUR 174.62 on October 8, 2026 at 4:12 p.m. CEST, minus 0.07 percent versus the prior close of EUR 174.75 on October 7, 2026. The primary-market quote was USD 195.66 at 10:25 a.m. ET, while market capitalization stood at USD 77.6 billion and the 52-week range was USD 22.28 to USD 212.22 on October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of Moderna stock.